Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | BRAF | P15056 | 3/20 | 0.59 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | KRAS | P01116 | 1/20 | 0.59 |
| ▸ | RAF1 | P04049 | 1/20 | 0.59 |
| ▸ | PGR | P06401 | 1/20 | 0.59 |
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | ARAF | P10398 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.59 |
| ▸ | FECH | P22830 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29898648 | 1.00 | MAP2K4 (0.62) | MAP2K4CYP2C19CYP2C9CYP3A4BRAF | |
| SCHEMBL26112471 | 0.90 | BRAF (0.65) | MAP2K4CYP2C19CYP2C9CYP3A4BRAF | |
| SCHEMBL29898661 | 0.90 | CYP2C19 (0.63) | MAP2K4CYP2C19CYP2C9CYP3A4BRAF | |
| SCHEMBL26111112 | 0.90 | CYP2C19 (0.63) | MAP2K4CYP2C19CYP2C9CYP3A4BRAF | |
| SCHEMBL30597846 | 0.90 | BRAF (0.65) | MAP2K4CYP2C19CYP2C9CYP3A4BRAF | |
| SCHEMBL26109796 | 0.90 | CYP2C19 (0.63) | MAP2K4CYP2C19CYP2C9CYP3A4BRAF | |
| SCHEMBL30597847 | 0.90 | CYP2C19 (0.63) | MAP2K4CYP2C19CYP2C9CYP3A4BRAF | |
| SCHEMBL30597833 | 0.89 | CYP2C19 (0.62) | MAP2K4CYP2C19CYP2C9CYP3A4BRAF | |
| SCHEMBL29898634 | 0.89 | MAP2K4 (0.64) | MAP2K4CYP2C19CYP2C9CYP3A4BRAF | |
| SCHEMBL26111567 | 0.89 | CYP2C19 (0.62) | MAP2K4CYP2C19CYP2C9CYP3A4BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | HEPAREGENIX GMBH (DE) | 2024-02-27 | — | — | US | disclosed |
| WO-2023194443-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF COLON AND LUNG CANCER | HEPAREGENIX GMBH (DE) | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912701-B2 | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death | MAPK4, MAPK7, MAPK14 | MAP2K4 22/4885CYP2C19 2763/4885CYP2C9 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.